Search:
This item requires a subscription.
The clinical management of mantle cell lymphoma BJCM, Volume 2, Number 2.
The management of mantle cell lymphoma (MCL) presents some particular difficulties to the clinician. It is now clear that as a distinct entity within the non-Hodgkin’s lymphomas (NHL), MCL has the worst prognosis of all subtypes, with a five-year survival rate of around 27%.1 While many patients will respond to firstline therapy, this response is rarely complete and a large proportion of patients will relapse within 18 months,2 at which point further treatment is often inadequate.
To view this item, select one of the options below:
Purchase access
Sign in
email address
Password
Important
All the articles are in PDF format.
To view the articles you will need Adobe Acrobat Reader.
To download a copy, free of charge, please click here.